

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 16 February 2015** – On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.

Under the programme initiated 30 January 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 30 January 2015 to 28 April 2015.

Since the announcement as of 9 February 2015, the following transactions have been made under the programme:

	<b>Number of B shares</b>	<b>Average purchase price</b>	<b>Transaction value, DKK</b>
<b>Accumulated, last announcement</b>	<b>1,320,000</b>		<b>379,994,272</b>
9 February 2015	235,000	275.94	64,846,182
10 February 2015	195,000	279.32	54,467,342
11 February 2015	216,481	281.04	60,840,600
12 February 2015	220,000	281.22	61,868,884
13 February 2015	200,000	284.13	56,826,800
<b>Accumulated under the programme</b>	<b>2,386,481</b>		<b>678,844,079</b>

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 316,545 B shares in the period from 9 February 2015 to 13 February 2015. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 61,185,354 B shares of DKK 0.20, corresponding to 2.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2015. As of 13 February 2015, Novo Nordisk has repurchased a total of 2,386,481 B shares equal to a transaction value of DKK 678,844,079.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)*

### Further information

#### Media:

Anne Margrethe Hauge +45 3079 3450 [amhg@novonordisk.com](mailto:amhg@novonordisk.com)

#### Investors:

Kasper Roseeuw Poulsen +45 3079 4303 [krop@novonordisk.com](mailto:krop@novonordisk.com)

Jannick Lindegaard Denholt +45 3079 8519 [jlis@novonordisk.com](mailto:jlis@novonordisk.com)

Daniel Bohsen +45 3079 6376 [dabo@novonordisk.com](mailto:dabo@novonordisk.com)

Melanie Raouzeos +45 3075 3479 [mrz@novonordisk.com](mailto:mrz@novonordisk.com)

Frank Daniel Mersebach (US) +1 609 235 8567 [fdni@novonordisk.com](mailto:fdni@novonordisk.com)